Beneficial effects of coenzyme Q10 supplementation on lipid profile and intereukin�6 and intercellular adhesion molecule�1 reduction, preliminary results of a double�blind trial in acute myocardial infarction

Background: The present investigation was aimed to improve the inflammatory factors and lipoproteins concentration in patients with myocardial infarction (MI) by supplementation with coenzyme Q10 (CoQ10). Methods: In a double�blind, placebo�controlled study, we measured serum concentrations of one soluble cell adhesion molecules (intercellular adhesion molecule�1 ICAM�1), serum concentration of intereukin�6 (IL�6) and lipid profiles (high�density lipoprotein�cholesterol HDL�C, low�density lipoprotein�cholesterol LDL�C, total cholesterol and triglyceride TG) in CoQ10 supplementation group (n = 26) compared with placebo group (n = 26) in hyperlipidemic patients with MI. Fifty�two patients were randomized to receive 200 mg/day of CoQ10 or placebo for 12 weeks. Results: There were no significant differences for serum LDL�C, total cholesterol, and TG between two mentioned groups after the intervention. A significant enhancement in serum HDL�C level was observed between groups after the intervention (55.46 ± 6.87 and 44.07 ± 6.99 mg/dl in CoQ10 and placebo groups, respectively P< 0.001). Concentrations of ICAM�1 (415.03 ± 96.89 and 453.38 ± 0.7 ng/dl CoQ10 and placebo groups, respectively, P = 0.001) and IL�6 (11 ± 9.57 and 12.55 ± 8.76 pg/ml CoQ10 and placebo groups, respectively P = 0.001) in serum were significantly decreased in CoQ10 group. Conclusions: Supplementation with CoQ10 in hyperlipidemic patients with MI that have statin therapy has beneficial effects on their aspects of health. © 2015 Mohseni M